Reach Us +44-1647-403003
Current Therapies for Malignant Mesothelioma | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article

Current Therapies for Malignant Mesothelioma

Anurag Shukla and Arti Shukla*
Department of Pathology, University of Vermont, College of Medicine, Burlington, VT, USA
Corresponding Author : Arti Shukla, PhD
Associate Professor, Pathology Department
University of Vermont, College of Medicine
89 Beaumont Avenue, Burlington, VT05405, USA
Tel: 802-656-8253
Fax: 802-656-8892
E-mail: [email protected]
Received July 15, 2014; Accepted August 18, 2014; Published August 25, 2014
Citation: Shukla A, Shukla A (2014) Current Therapies for Malignant Mesothelioma. J Cancer Sci Ther 6:306-309. doi:10.4172/1948-5956.1000285
Copyright: © 2014 Shukla A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Malignant mesothelioma (MM) is a deadly cancer caused by asbestos exposure that is increasing worldwide. Early diagnosis for this cancer is very difficult and MM is mostly resistant to conventional therapies. A host of factors may be responsible for development of MM and imparting drug resistance to this cancer. Understanding these processes will be important in designing therapeutic approaches for MM. Some of the conventional as well as current approaches for MM therapy are discussed in this review.